Details
Open$0.27
$0.27
The price of this investment when the exchange last opened.
High$0.30
$0.30
The highest price of this investment during regular trading hours.
Low$0.27
$0.27
The lowest price of this investment during regular trading hours.
Mkt cap44.8M
44.8M
The value of this ETF or company's issued shares based on the price of a single share multiplied by the total number of issued shares.
P/E ratio
The price to earnings ratio (P/E) is the relationship between an investment's price and earnings per share (EPS). It's a metric that can be used to determine the valuation or potential growth of an investment based on its past or future earnings. It's calculated by dividing the share price by EPS.
52-wk high$0.80
$0.80
The highest price this investment has been in the past 52 weeks.
52-wk low$0.21
$0.21
The lowest price this investment has been in the past 52 weeks.
Volume497K
497K
The total number of shares bought and sold.
EPS (TTM)-0.08
-0.08
Earnings per share (EPS) is the amount of profit a company generated for each outstanding share of its common stock. It is often used as an indicator of company profitability.
About IN
InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
CEO
Eric A. Adams
Headquarters
Canada
Employees
12
Revenue (TTM)
0
Gross Profit
Earnings
-47.00%
Cash
$14.7M
Debt
$504K
